Q2 FY2026 · ended Jun 30, 2026 · Revenue $24,245, +30.0% YoY · Filed Aug 14, 2026
Jupiter Neurosciences, Inc. (JUNS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $24,245 and a net loss of $2.3 million. As of Jun 30, 2026 it held $1.5 million in cash and investments and $220,607 in total debt.
Revenue
$24,245
+30.0% vs prior quarter
Net income
$-2.27M
-1.0% vs year-ago quarter
Operating cash flow
$-2.29M
-177.1% vs year-ago quarter
Free cash flow
—
EPS
$-4.08
+19.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
770,081
-97.8% vs year-ago quarter
Net cash
$1.30M
Q2 FY2026
Operating margin
-11313.4%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JUNS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jupiter, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1679628
- Former names
- Jupiter Orphan Therapeutics, Inc. (until Dec 5, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $24,245 | $18,652 | — | — | — |
| Operating income | -$2.7M | -$2.0M | -$2.8M | -$2.3M | -$2.3M |
| Net income | -$2.3M | -$2.1M | -$2.6M | -$2.3M | -$2.3M |
| Diluted EPS | -$4.08 | -$0.06 | -$0.07 | -$0.07 | -$5.09 |
| Operating cash flow | -$2.3M | -$1.4M | -$2.4M | -$1.2M | -$828,222 |
| Total assets | $3.7M | $3.9M | $5.6M | $2.6M | $4.0M |
| Total liabilities | $4.1M | $6.7M | $7.4M | $2.5M | $2.6M |
| Stockholders' equity | -$365,966 | -$2.8M | -$1.8M | $57,417 | $1.3M |
| Cash and investments | $1.5M | $2.4M | $3.8M | $723,797 | $1.9M |
| Total debt | $220,607 | $8,508 | $21,247 | $33,961 | $46,428 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 3, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Aug 27, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 24, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 203 Jupiter Neurosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.